comparemela.com

Trend Honor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D.,.

Kenji yasukawaKlaus gieseTaiji sawamotoBrandenburg innovationsforumAstellas pharma incResearch operationsDrug developmentAstellas pharmaPantherna therapeutics gmbhChief executive officerExecutive vice presidentApplied researchFocus areaFocus area approachTrend honorInnovative product

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D.,.

Kenji yasukawaKlaus gieseTaiji sawamotoBrandenburg innovationsforumAstellas pharma incResearch operationsDrug developmentAstellas pharmaPantherna therapeutics gmbhChief executive officerExecutive vice presidentApplied researchFocus areaFocus area approachTrend honorInnovative product

vimarsana © 2020. All Rights Reserved.